サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1480862

呼吸器合胞体ウイルス（RSV）治療薬の世界市場

Respiratory Syncytial Virus (RSV) Therapeutics
出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 194 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=153.16円
呼吸器合胞体ウイルス（RSV）治療薬の世界市場
出版日: 2024年05月20日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 194 Pages
納期: 即日から翌営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

呼吸器合胞体ウイルス（RSV）治療薬の世界市場は2030年までに78億米ドルに到達

2023年に13億米ドルと推定された呼吸器合胞体ウイルス（RSV）治療薬の世界市場は、2023年から2030年にかけて29.1%のCAGRで成長し、2030年には78億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである予防薬は、CAGR 28.3%を記録し、分析期間終了時には68億米ドルに達すると予測されます。RSV治療薬セグメントは、今後7年間のCAGRが34.7%と予測されます。

米国市場は推定4億630万米ドル、中国はCAGR 27.9％で成長予測

米国の呼吸器合胞体ウイルス（RSV）治療薬市場は、2023年に4億630万米ドルと推定されます。世界第2位の経済大国である中国は、2023年から2030年までの分析期間においてCAGR 27.9%で推移し、2030年には13億米ドルの市場規模に達すると予測されています。その他の注目すべき地域市場としては、日本とカナダがあり、それぞれ2023年から2030年にかけて26.1%と24.8%の成長が予測されています。欧州では、ドイツが約20.2％のCAGRで成長すると予測されています。

2024年の魅力的な新レポート機能のご紹介

インフルエンサーのエンゲージメント統計へのフルアクセス

デジタルアーカイブと「MarketGlass」調査プラットフォームへの無料アクセス。当社独自のMarketGlassプラットフォームは、世界中の専門家の創造性と市場知識を統合的かつ協調的に解き放つことができます。当社の最先端のツールは、市場参入企業のプライバシーとアイデンティティを保護しながら、世界クラスの市場展望をもたらします。レポート内の数字、統計、市場に関する説明は、この分野の専門家や影響力のある人々によって共有された、完全にキュレートされた洞察に基づいています。

リアルタイムのデータシミュレーター・ツールや特注のレポート作成機能を備えたインタラクティブなアンケートに参加できます。

企業間のスマートな意見交換のためのピアコラボレーティブ・インタラクティブプラットフォームへのフルクライアントアクセス

1年間の無料レポート更新

主要プレーヤーの世界市場シェアを含む競合カバレッジ

複数の地域にまたがるプレーヤーの市場プレゼンス分析（好調/活発/ニッチ/マイナー）

専門家/インフルエンサーのインタビュー、ポッドキャスト、プレス発表、イベント基調講演のYouTubeビデオへのアクセス

2024年の世界経済に期待すること

金融引き締めとそれに伴う金利上昇によって引き起こされる地政学的、経済的不安定性が、2024年の激動の情勢を作り出すと思われます。中東での敵対行為や、ますます頻発する気候災害など、いくつかの要因が回復への道筋に圧力をかけ続けると思われます。リスクの一方で、ディスインフレの兆候が強まり、頑迷なインフレに対する不安が緩和され、サプライチェーンが正常化し、エネルギーコストの変動にもかかわらず物価が緩やかになるなど、いくつかのプラス材料も具体化しつつあります。インドや米国をはじめとするG21諸国の選挙は、資本の流れや投資戦略に影響を与える可能性があります。インドが世界な投資先として注目される一方で、米国を拠点とするハイテク企業は、才能と資本のダイナミックなエコシステムに後押しされ、引き続き優位を保つと思われます。シリコンバレーをはじめとするハイテク機会は、国内経済が減速しているとはいえ底堅く、規制環境も整備されていることから、高成長の可能性を求める投資家にとって引き続き魅力的です。欧州は金融引き締め政策と景気後退リスクとの戦いが続くが、英国は見通しが最も厳しく、2024年の景気後退リスクが最も高いです。中国は、政府支出と個人消費の改善に支えられた成長が期待されるもの、引き続きワイルドカードとなります。不安定な環境は、投資家にも企業にもチャンスと課題の両方をもたらすと思われます。成長への触媒としてボラティリティを受け入れるとともに、敏捷性と戦略的な先見性をもって投資判断に臨むことが、生き残りのために重要であることに変わりはないです。

調査対象企業の例（全41件）

  • AbbVie, Inc.
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Merck & Co., Inc.
  • ReViral Ltd.
  • Teva Pharmaceutical Industries Ltd.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • 世界のその他の地域

第4章 競合

目次
Product Code: MCP16752

Global Respiratory Syncytial Virus (RSV) Therapeutics Market to Reach $7.8 Billion by 2030

The global market for Respiratory Syncytial Virus (RSV) Therapeutics estimated at US$1.3 Billion in the year 2023, is expected to reach US$7.8 Billion by 2030, growing at a CAGR of 29.1% over the period 2023-2030. Prophylaxis Drugs, one of the segments analyzed in the report, is expected to record 28.3% CAGR and reach US$6.8 Billion by the end of the analysis period. Growth in the RSV Treatment segment is estimated at 34.7% CAGR for the next 7-year period.

The U.S. Market is Estimated at $406.3 Million, While China is Forecast to Grow at 27.9% CAGR

The Respiratory Syncytial Virus (RSV) Therapeutics market in the U.S. is estimated at US$406.3 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.3 Billion by the year 2030 trailing a CAGR of 27.9% over the analysis period 2023 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 26.1% and 24.8% respectively over the 2023-2030 period. Within Europe, Germany is forecast to grow at approximately 20.2% CAGR.

Introducing Our Exciting New Report Features for 2024

Full access to influencer engagement stats

Free access to our digital archives & "MarketGlass" research platform. Our proprietary MarketGlass platform is fully enabled to unlock creativity and market knowledge of domain experts worldwide in a cohesive and collaborative manner. Our state-of-art tools bring world class market perspectives while protecting participants' privacy and identity. Numbers, statistics and market narrative in the report are based on fully curated insights shared by domain experts and influencers in this space.

Opportunity to engage with interactive questionnaires that come with real-time data simulator tools & bespoke report generation capabilities

Full client access to peer collaborative and interactive platform for cross-enterprise smart exchange of ideas

Complimentary report updates for one year

Competitor coverage with global market shares of major players

Player market presence analysis (Strong/Active/Niche/Trivial) across multiple geographies

Access to curated YouTube video transcripts of domain experts/influencer interviews, podcasts, press statements and event keynotes

What to Expect from the Global Economy in 2024

Edgy geopolitics, and economic instability caused by monetary policy tightening and ensuing higher interest rates will create a tumultuous landscape for 2024. Several factors will continue to exert pressure on the path to recovery including hostilities in the Middle East and increasingly common climate disasters. Among the risks, several positives are also taking shape such as growing signs of disinflation and easing of anxiety over stubborn inflation, supply chain normalization and price moderation despite volatility in energy costs. Elections across several G21 jurisdictions, notably in India and the United States, will have potential ramifications for capital flows and investment strategies. While India emerges as a compelling destination in the global investment landscape, U.S, based tech firms will continue to dominate, fueled by a dynamic ecosystem of talent and capital. Tech opportunities in Silicon Valley and beyond remain attractive for investors seeking high-growth prospects supported largely by a resilient albeit slowing domestic economy and conducive regulatory environment. Europe will continue to battle tight monetary policy and recession risks with U.K. having the most challenging outlook and running the greatest risk of recession in 2024. China remains a wild card with hope for growth in the country underpinned by government spending and improvements in consumer spending. The volatile environment will offer both opportunities and challenges for investors and businesses alike. Embracing volatility as a catalyst for growth together with agility and strategic foresight in navigating investment decisions will remain important for survival.

Select Competitors (Total 41 Featured) -

  • AbbVie, Inc.
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Merck & Co., Inc.
  • ReViral Ltd.
  • Teva Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Respiratory Syncytial Virus (RSV) Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Prophylaxis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Prophylaxis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Prophylaxis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Hospital Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Retail Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Online by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Online by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Online by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Respiratory Syncytial Virus (RSV) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Prophylaxis and Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Prophylaxis and Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prophylaxis and Treatment for the Years 2014, 2024 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Prophylaxis and Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Prophylaxis and Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prophylaxis and Treatment for the Years 2014, 2024 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
  • JAPAN
    • Respiratory Syncytial Virus (RSV) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Prophylaxis and Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Prophylaxis and Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prophylaxis and Treatment for the Years 2014, 2024 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
  • CHINA
    • Respiratory Syncytial Virus (RSV) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Prophylaxis and Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Prophylaxis and Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: China 16-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prophylaxis and Treatment for the Years 2014, 2024 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: China 16-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
  • EUROPE
    • Respiratory Syncytial Virus (RSV) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Prophylaxis and Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Prophylaxis and Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prophylaxis and Treatment for the Years 2014, 2024 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
  • FRANCE
    • Respiratory Syncytial Virus (RSV) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Prophylaxis and Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Prophylaxis and Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: France 16-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prophylaxis and Treatment for the Years 2014, 2024 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: France 16-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
  • GERMANY
    • Respiratory Syncytial Virus (RSV) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Prophylaxis and Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Prophylaxis and Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prophylaxis and Treatment for the Years 2014, 2024 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Prophylaxis and Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Prophylaxis and Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prophylaxis and Treatment for the Years 2014, 2024 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Respiratory Syncytial Virus (RSV) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Prophylaxis and Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Prophylaxis and Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prophylaxis and Treatment for the Years 2014, 2024 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 77: Rest of Europe Recent Past, Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Prophylaxis and Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Rest of Europe Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Prophylaxis and Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: Rest of Europe 16-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prophylaxis and Treatment for the Years 2014, 2024 & 2030
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Rest of Europe Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: Rest of Europe 16-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Respiratory Syncytial Virus (RSV) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 83: Asia-Pacific Recent Past, Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Prophylaxis and Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Asia-Pacific Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Prophylaxis and Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Asia-Pacific 16-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prophylaxis and Treatment for the Years 2014, 2024 & 2030
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Asia-Pacific 16-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 89: Rest of World Recent Past, Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Prophylaxis and Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Rest of World Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Prophylaxis and Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Rest of World 16-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Prophylaxis and Treatment for the Years 2014, 2024 & 2030
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of World Historic Review for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of World 16-Year Perspective for Respiratory Syncytial Virus (RSV) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030

IV. COMPETITION